Raymond James Financial Inc. Takes $9.65 Million Position in LivaNova PLC (NASDAQ:LIVN)

Raymond James Financial Inc. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 208,276 shares of the company's stock, valued at approximately $9,645,000. Raymond James Financial Inc. owned approximately 0.38% of LivaNova at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB lifted its stake in LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock valued at $3,188,000 after acquiring an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in shares of LivaNova during the 4th quarter valued at $1,954,000. KBC Group NV lifted its stake in shares of LivaNova by 130.5% in the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the last quarter. Rhumbline Advisers boosted its holdings in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after purchasing an additional 899 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock worth $32,678,000 after buying an additional 93,311 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on LIVN shares. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 26th. Finally, Barclays lowered their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LivaNova currently has an average rating of "Moderate Buy" and a consensus price target of $61.17.

Remove Ads

LivaNova Stock Performance

NASDAQ:LIVN traded down $0.45 during trading hours on Tuesday, hitting $39.92. 458,433 shares of the company traded hands, compared to its average volume of 594,494. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $36.85 and a twelve month high of $64.48. The firm has a 50-day moving average of $45.17 and a 200 day moving average of $48.70. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of 95.05 and a beta of 1.10.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.